4Wise R, Brenwald N P, Andrews J M, Boswell F. The activity of methypiperazinyl fluoroquinolne CG 5501: a comparison with other fluoroquinolones[J]. J Antimicrob Chemother 1997, 39:447-52
5Hong C Y, Kim Y K, Nam D -H etc. SB -265805: structure -activity relationship of the oxime-derivatized pyrrolidine. The importance of the oximinoalkyl group on in vitro antibacterial activity and pharmacokinetics. In Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego[N].CA, 1998:Poster F-095
6Jone M E, Visser M R, Klootwijk M, Heisig P, Verhofe J. Schmitz F-J.Comparative activites of clinafloxacin,grepafloxacin, levofloxacin and nonquinolnes linezolid, quinupristin-dalfopristin, gentamicin,and vancomycin against clinical isolates of ciprofloxacin -resistant and susceptible Staphylococcus aureus strains [J].Antimicrob Agents Chemother 1999,43:421~423.
7Ronald N. Jones, Douglas J., Biedenbach. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from communityacquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999 -2001). [J] .Diagnostic Microbiology and InfectiousDisease. 2003, (45): 273-278.
8Koruznjak J D, Grdisa M, Slade N. etal. Novel derivative sofbenzo [b]thieno [2,3 c] quinolones: synthesis, photochemicalsynthesis, and antitumorevaluation [J] .J. MedChem, 2003, 46: 4516.
9Lohray B B, Baskaran S, Rao B S,etc. Novel quinolone derivative saspoten antibacterials [J]. Bioorg Med Chem Lett, 1998,8:525~52.
10Yun S, Jung, Y, Lee J. etc. Antimicrobial quinolone derivatives and process for the preparation [P].KR9703501,1997-05-18.